Vermillion (VRML) continues its wild ride upward from the November low of $4.53 on heavy volume of 546K shares with no apparent news. Two analysts cover the stock with a buy/outperform and Revenue Forecasts in the $7M range for Year Ending Dec.’11 and a Price Target of 10. The market cap is $93M. The stock price high for the year is 34. Vermillion is pure play diagnostic Company focused on unique biomarkers and recently has an approved test OVA1 a test for Ovarian cancer.
- Groups sue over Alabama abortion law; judge blocks Mississippi ban May 25, 2019
- Mexico budget cuts hit patient care and delay kids' surgeries, doctors warn May 24, 2019
- Novartis $2 million gene therapy for rare disorder is world's most expensive drug May 24, 2019
- Doctor, medical funder charged in New York in transvaginal mesh fraud May 24, 2019
2009-2017 Life Science Portfolios 2018 Rayno Biopharmaceuticals Portfolio 2018 Rayno Tools and Diagnostics Portfolio BIOgraph Biopharmaceuticals Clinical Diagnostics and Tools Energy Life Science ETF's and Mutual Funds Macro RAG Rayno Life Science Portfolio Reading List Weather//Ski Reports-Western US Weather Snow Reports West Coast